First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-03-26

AUTHORS

Christophe Massard, Jean-Charles Soria, Jürgen Krauss, Michael Gordon, Albert Craig Lockhart, Erik Rasmussen, Vijay V. Upreti, Sonal Patel, Gataree Ngarmchamnanrith, Haby Henary

ABSTRACT

PURPOSE: This study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory clear cell renal cell carcinoma (ccRCC). METHODS: This was an open-label, adaptive dose-exploration study in patients with relapsed/refractory ccRCC. The study was conducted in two parts for dose exploration and dose expansion on a biweekly dosing schedule. AMG 172 doses of 0.15, 0.3, 0.6, 1.2, 1.6, 1.8, and 2.4 mg/kg were studied in the dose-exploration phase. RESULTS: The 1.6 mg/kg dose of AMG 172 was identified as the maximum tolerated dose (MTD). The most common adverse events were thrombocytopenia (59%), nausea (54%), decreased appetite (49%), vomiting (46%), and fatigue (35%). The most common dose-limiting toxicity (DLT) was thrombocytopenia. Thrombocytopenia and liver injury constituted DLTs that required discontinuation of treatment. Of the 10 patients treated at the MTD in part 2 of the study, 2 patients had grade 3 hepatocellular injury with aspartate aminotransferase or alanine aminotransferase elevation. Pharmacokinetic profiles indicated low levels of circulating unconjugated antibody and unconjugated cytotoxin. Dose-proportional increases in plasma exposure were observed over the dose range of 0.3-2.4 mg/kg. Following multiple biweekly doses, plasma accumulation was less than two-fold. Two patients (5.4%) had a partial response, 6 patients (16.2%) had stable disease, and 13 patients (35.1%) had progressive disease. CONCLUSION: AMG 172 exhibited a favorable pharmacokinetic profile in patients with relapsed/refractory ccRCC and showed evidence suggestive of limited antitumor activity. Safety and tolerability were as expected for a maytansinoid antibody-drug conjugate. More... »

PAGES

1-7

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00280-019-03796-4

DOI

http://dx.doi.org/10.1007/s00280-019-03796-4

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1113011619

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30915497


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Institut Gustave Roussy", 
          "id": "https://www.grid.ac/institutes/grid.14925.3b", 
          "name": [
            "Drug Development Department (DITEP), Inserm Unit U981, Universit\u00e9 Paris Saclay, Universit\u00e9 Paris-Sud, Gustave Roussy, Villejuif, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Massard", 
        "givenName": "Christophe", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut Gustave Roussy", 
          "id": "https://www.grid.ac/institutes/grid.14925.3b", 
          "name": [
            "Drug Development Department (DITEP), Inserm Unit U981, Universit\u00e9 Paris Saclay, Universit\u00e9 Paris-Sud, Gustave Roussy, Villejuif, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Soria", 
        "givenName": "Jean-Charles", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University Hospital Heidelberg", 
          "id": "https://www.grid.ac/institutes/grid.5253.1", 
          "name": [
            "Department of Medical Oncology, National Center for Tumor Diseases (NCT), Im Neuenheimer Feld 460, 69120, Heidelberg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Krauss", 
        "givenName": "J\u00fcrgen", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "HonorHealth", 
          "id": "https://www.grid.ac/institutes/grid.477855.c", 
          "name": [
            "HonorHealth Research Institute, 9055 E Del Camino Dr. #100, 85258, Scottsdale, AZ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gordon", 
        "givenName": "Michael", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sylvester Comprehensive Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.419791.3", 
          "name": [
            "Sylvester Comprehensive Cancer Center, University of Miami, 1475 NW 12th Ave, 33136, Miami, FL, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lockhart", 
        "givenName": "Albert Craig", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amgen (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417886.4", 
          "name": [
            "Amgen Inc., 91320, Thousand Oaks, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rasmussen", 
        "givenName": "Erik", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amgen (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417886.4", 
          "name": [
            "Amgen Inc., 94080, South San Francisco, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Upreti", 
        "givenName": "Vijay V.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amgen (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417886.4", 
          "name": [
            "Amgen Inc., 94080, South San Francisco, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Patel", 
        "givenName": "Sonal", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amgen (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417886.4", 
          "name": [
            "Amgen Inc., 91320, Thousand Oaks, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ngarmchamnanrith", 
        "givenName": "Gataree", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amgen (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417886.4", 
          "name": [
            "Amgen Inc., 91320, Thousand Oaks, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Henary", 
        "givenName": "Haby", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1021/bc400217g", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002281065"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.humpath.2011.10.014", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009539020"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6603222", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015553357", 
          "https://doi.org/10.1038/sj.bjc.6603222"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6603222", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015553357", 
          "https://doi.org/10.1038/sj.bjc.6603222"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-15-1542", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015608968"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ijc.10207", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022398738"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00000478-200005000-00014", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023798968"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00000478-200005000-00014", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023798968"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00000478-200005000-00014", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023798968"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.2015.412", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025273041", 
          "https://doi.org/10.1038/bjc.2015.412"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-015-2909-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025883872", 
          "https://doi.org/10.1007/s00280-015-2909-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4049/jimmunol.174.2.710", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027349643"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-05-2883", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027810770"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10637-014-0151-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028323868", 
          "https://doi.org/10.1007/s10637-014-0151-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/10543409808835252", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038293418"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0092-8674(93)90133-b", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038946067"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1083/jcb.201006102", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040781778"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/978-1-62703-050-2_16", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046629425", 
          "https://doi.org/10.1007/978-1-62703-050-2_16"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/01.ju.0000158121.49085.ba", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049100456"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/01.ju.0000158121.49085.ba", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049100456"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/01.ju.0000158121.49085.ba", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049100456"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/intimm/6.3.477", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059712108"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1535-7163.mct-16-0393", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1063226571"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/009286150303700108", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1063723113"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/009286150303700108", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1063723113"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082404835", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.6004/jnccn.2017.0100", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085942145"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.6004/jnccn.2017.0100", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085942145"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.eururo.2018.03.036", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1103237587"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-03-26", 
    "datePublishedReg": "2019-03-26", 
    "description": "PURPOSE: This study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory clear cell renal cell carcinoma (ccRCC).\nMETHODS: This was an open-label, adaptive dose-exploration study in patients with relapsed/refractory ccRCC. The study was conducted in two parts for dose exploration and dose expansion on a biweekly dosing schedule. AMG 172 doses of 0.15, 0.3, 0.6, 1.2, 1.6, 1.8, and 2.4\u00a0mg/kg were studied in the dose-exploration phase.\nRESULTS: The 1.6\u00a0mg/kg dose of AMG 172 was identified as the maximum tolerated dose (MTD). The most common adverse events were thrombocytopenia (59%), nausea (54%), decreased appetite (49%), vomiting (46%), and fatigue (35%). The most common dose-limiting toxicity (DLT) was thrombocytopenia. Thrombocytopenia and liver injury constituted DLTs that required discontinuation of treatment. Of the 10 patients treated at the MTD in part 2 of the study, 2 patients had grade 3 hepatocellular injury with aspartate aminotransferase or alanine aminotransferase elevation. Pharmacokinetic profiles indicated low levels of circulating unconjugated antibody and unconjugated cytotoxin. Dose-proportional increases in plasma exposure were observed over the dose range of 0.3-2.4\u00a0mg/kg. Following multiple biweekly doses, plasma accumulation was less than two-fold. Two patients (5.4%) had a partial response, 6 patients (16.2%) had stable disease, and 13 patients (35.1%) had progressive disease.\nCONCLUSION: AMG 172 exhibited a favorable pharmacokinetic profile in patients with relapsed/refractory ccRCC and showed evidence suggestive of limited antitumor activity. Safety and tolerability were as expected for a maytansinoid antibody-drug conjugate.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00280-019-03796-4", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1088364", 
        "issn": [
          "0344-5704", 
          "1432-0843"
        ], 
        "name": "Cancer Chemotherapy and Pharmacology", 
        "type": "Periodical"
      }
    ], 
    "name": "First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinoma", 
    "pagination": "1-7", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "ecdeadb0eadb363a996d2bca8fc9a132afe0bca4b2afc304ba68f926af4157f5"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30915497"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7806519"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00280-019-03796-4"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1113011619"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00280-019-03796-4", 
      "https://app.dimensions.ai/details/publication/pub.1113011619"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T13:08", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000367_0000000367/records_88230_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs00280-019-03796-4"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00280-019-03796-4'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00280-019-03796-4'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00280-019-03796-4'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00280-019-03796-4'


 

This table displays all metadata directly associated to this object as RDF triples.

199 TRIPLES      21 PREDICATES      48 URIs      18 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00280-019-03796-4 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N0c6ddfb44e3d4e2baf6db98788257800
4 schema:citation sg:pub.10.1007/978-1-62703-050-2_16
5 sg:pub.10.1007/s00280-015-2909-2
6 sg:pub.10.1007/s10637-014-0151-0
7 sg:pub.10.1038/bjc.2015.412
8 sg:pub.10.1038/sj.bjc.6603222
9 https://app.dimensions.ai/details/publication/pub.1082404835
10 https://doi.org/10.1002/ijc.10207
11 https://doi.org/10.1016/0092-8674(93)90133-b
12 https://doi.org/10.1016/j.eururo.2018.03.036
13 https://doi.org/10.1016/j.humpath.2011.10.014
14 https://doi.org/10.1021/bc400217g
15 https://doi.org/10.1080/10543409808835252
16 https://doi.org/10.1083/jcb.201006102
17 https://doi.org/10.1093/intimm/6.3.477
18 https://doi.org/10.1097/00000478-200005000-00014
19 https://doi.org/10.1097/01.ju.0000158121.49085.ba
20 https://doi.org/10.1158/0008-5472.can-05-2883
21 https://doi.org/10.1158/1078-0432.ccr-15-1542
22 https://doi.org/10.1158/1535-7163.mct-16-0393
23 https://doi.org/10.1177/009286150303700108
24 https://doi.org/10.4049/jimmunol.174.2.710
25 https://doi.org/10.6004/jnccn.2017.0100
26 schema:datePublished 2019-03-26
27 schema:datePublishedReg 2019-03-26
28 schema:description PURPOSE: This study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory clear cell renal cell carcinoma (ccRCC). METHODS: This was an open-label, adaptive dose-exploration study in patients with relapsed/refractory ccRCC. The study was conducted in two parts for dose exploration and dose expansion on a biweekly dosing schedule. AMG 172 doses of 0.15, 0.3, 0.6, 1.2, 1.6, 1.8, and 2.4 mg/kg were studied in the dose-exploration phase. RESULTS: The 1.6 mg/kg dose of AMG 172 was identified as the maximum tolerated dose (MTD). The most common adverse events were thrombocytopenia (59%), nausea (54%), decreased appetite (49%), vomiting (46%), and fatigue (35%). The most common dose-limiting toxicity (DLT) was thrombocytopenia. Thrombocytopenia and liver injury constituted DLTs that required discontinuation of treatment. Of the 10 patients treated at the MTD in part 2 of the study, 2 patients had grade 3 hepatocellular injury with aspartate aminotransferase or alanine aminotransferase elevation. Pharmacokinetic profiles indicated low levels of circulating unconjugated antibody and unconjugated cytotoxin. Dose-proportional increases in plasma exposure were observed over the dose range of 0.3-2.4 mg/kg. Following multiple biweekly doses, plasma accumulation was less than two-fold. Two patients (5.4%) had a partial response, 6 patients (16.2%) had stable disease, and 13 patients (35.1%) had progressive disease. CONCLUSION: AMG 172 exhibited a favorable pharmacokinetic profile in patients with relapsed/refractory ccRCC and showed evidence suggestive of limited antitumor activity. Safety and tolerability were as expected for a maytansinoid antibody-drug conjugate.
29 schema:genre research_article
30 schema:inLanguage en
31 schema:isAccessibleForFree false
32 schema:isPartOf sg:journal.1088364
33 schema:name First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinoma
34 schema:pagination 1-7
35 schema:productId N254de6d6002a4580a0fe3e8331c60dbf
36 N608fed71b49b44aa81fe76506b558a9e
37 N73e6d889df814d1e9f12be8fd23512ad
38 N829c4edd52954820af40df5d7336369f
39 N8e8acb56b55b494d8844f665cd32eba8
40 schema:sameAs https://app.dimensions.ai/details/publication/pub.1113011619
41 https://doi.org/10.1007/s00280-019-03796-4
42 schema:sdDatePublished 2019-04-11T13:08
43 schema:sdLicense https://scigraph.springernature.com/explorer/license/
44 schema:sdPublisher Ncb8025784c074d5590e6f106bfcf3acd
45 schema:url https://link.springer.com/10.1007%2Fs00280-019-03796-4
46 sgo:license sg:explorer/license/
47 sgo:sdDataset articles
48 rdf:type schema:ScholarlyArticle
49 N0031887ab9e84c3fab163d1b9d70cac0 rdf:first N50a532ccbfb94745a81013b08c3083a2
50 rdf:rest N86ca2f96871b47b1b1f2a28a115d1baf
51 N011e321798ee45fa9d0247a016d1d6b8 rdf:first N83930eb6b1b843aa92cc845a2588e20c
52 rdf:rest N74263e1184cd41a593ab296a0bf85316
53 N0c6ddfb44e3d4e2baf6db98788257800 rdf:first N30706fe239e4411d96350969fd0ea1d5
54 rdf:rest Nfc034b33fd194a6c9eab6678cd6dd3b3
55 N254de6d6002a4580a0fe3e8331c60dbf schema:name doi
56 schema:value 10.1007/s00280-019-03796-4
57 rdf:type schema:PropertyValue
58 N30706fe239e4411d96350969fd0ea1d5 schema:affiliation https://www.grid.ac/institutes/grid.14925.3b
59 schema:familyName Massard
60 schema:givenName Christophe
61 rdf:type schema:Person
62 N310be90aa40f4668ba05ea2c7c6b9a8a schema:affiliation https://www.grid.ac/institutes/grid.417886.4
63 schema:familyName Ngarmchamnanrith
64 schema:givenName Gataree
65 rdf:type schema:Person
66 N50a532ccbfb94745a81013b08c3083a2 schema:affiliation https://www.grid.ac/institutes/grid.417886.4
67 schema:familyName Patel
68 schema:givenName Sonal
69 rdf:type schema:Person
70 N608fed71b49b44aa81fe76506b558a9e schema:name pubmed_id
71 schema:value 30915497
72 rdf:type schema:PropertyValue
73 N611ebb13a51c42d097a37f569dfdc8d2 schema:affiliation https://www.grid.ac/institutes/grid.477855.c
74 schema:familyName Gordon
75 schema:givenName Michael
76 rdf:type schema:Person
77 N7067e387b5c64cb3b6f08a7e8cab6227 schema:affiliation https://www.grid.ac/institutes/grid.417886.4
78 schema:familyName Rasmussen
79 schema:givenName Erik
80 rdf:type schema:Person
81 N7374850e77a04738a9cb35e5f3b5791e schema:affiliation https://www.grid.ac/institutes/grid.14925.3b
82 schema:familyName Soria
83 schema:givenName Jean-Charles
84 rdf:type schema:Person
85 N73e6d889df814d1e9f12be8fd23512ad schema:name dimensions_id
86 schema:value pub.1113011619
87 rdf:type schema:PropertyValue
88 N74263e1184cd41a593ab296a0bf85316 rdf:first N611ebb13a51c42d097a37f569dfdc8d2
89 rdf:rest Nc03e26fd77d940e6b074d4f1cd2054f0
90 N829c4edd52954820af40df5d7336369f schema:name nlm_unique_id
91 schema:value 7806519
92 rdf:type schema:PropertyValue
93 N83930eb6b1b843aa92cc845a2588e20c schema:affiliation https://www.grid.ac/institutes/grid.5253.1
94 schema:familyName Krauss
95 schema:givenName Jürgen
96 rdf:type schema:Person
97 N8600e8aaeaea439695cd14e8516b36bd schema:affiliation https://www.grid.ac/institutes/grid.417886.4
98 schema:familyName Henary
99 schema:givenName Haby
100 rdf:type schema:Person
101 N86ca2f96871b47b1b1f2a28a115d1baf rdf:first N310be90aa40f4668ba05ea2c7c6b9a8a
102 rdf:rest Ncbdf4a8bece44deaafafc6f0cc45f9cc
103 N8e8acb56b55b494d8844f665cd32eba8 schema:name readcube_id
104 schema:value ecdeadb0eadb363a996d2bca8fc9a132afe0bca4b2afc304ba68f926af4157f5
105 rdf:type schema:PropertyValue
106 N91c22daa73b24cc0bd90c269abd30ef6 schema:affiliation https://www.grid.ac/institutes/grid.417886.4
107 schema:familyName Upreti
108 schema:givenName Vijay V.
109 rdf:type schema:Person
110 N968d4bc50f3f49f68941376434c00c7c schema:affiliation https://www.grid.ac/institutes/grid.419791.3
111 schema:familyName Lockhart
112 schema:givenName Albert Craig
113 rdf:type schema:Person
114 Nb60d5f4ef53c41088e56d65d16339862 rdf:first N7067e387b5c64cb3b6f08a7e8cab6227
115 rdf:rest Ncfaf0d70ca3a41ab92d4165d99b5b626
116 Nc03e26fd77d940e6b074d4f1cd2054f0 rdf:first N968d4bc50f3f49f68941376434c00c7c
117 rdf:rest Nb60d5f4ef53c41088e56d65d16339862
118 Ncb8025784c074d5590e6f106bfcf3acd schema:name Springer Nature - SN SciGraph project
119 rdf:type schema:Organization
120 Ncbdf4a8bece44deaafafc6f0cc45f9cc rdf:first N8600e8aaeaea439695cd14e8516b36bd
121 rdf:rest rdf:nil
122 Ncfaf0d70ca3a41ab92d4165d99b5b626 rdf:first N91c22daa73b24cc0bd90c269abd30ef6
123 rdf:rest N0031887ab9e84c3fab163d1b9d70cac0
124 Nfc034b33fd194a6c9eab6678cd6dd3b3 rdf:first N7374850e77a04738a9cb35e5f3b5791e
125 rdf:rest N011e321798ee45fa9d0247a016d1d6b8
126 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
127 schema:name Medical and Health Sciences
128 rdf:type schema:DefinedTerm
129 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
130 schema:name Clinical Sciences
131 rdf:type schema:DefinedTerm
132 sg:journal.1088364 schema:issn 0344-5704
133 1432-0843
134 schema:name Cancer Chemotherapy and Pharmacology
135 rdf:type schema:Periodical
136 sg:pub.10.1007/978-1-62703-050-2_16 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046629425
137 https://doi.org/10.1007/978-1-62703-050-2_16
138 rdf:type schema:CreativeWork
139 sg:pub.10.1007/s00280-015-2909-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025883872
140 https://doi.org/10.1007/s00280-015-2909-2
141 rdf:type schema:CreativeWork
142 sg:pub.10.1007/s10637-014-0151-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028323868
143 https://doi.org/10.1007/s10637-014-0151-0
144 rdf:type schema:CreativeWork
145 sg:pub.10.1038/bjc.2015.412 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025273041
146 https://doi.org/10.1038/bjc.2015.412
147 rdf:type schema:CreativeWork
148 sg:pub.10.1038/sj.bjc.6603222 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015553357
149 https://doi.org/10.1038/sj.bjc.6603222
150 rdf:type schema:CreativeWork
151 https://app.dimensions.ai/details/publication/pub.1082404835 schema:CreativeWork
152 https://doi.org/10.1002/ijc.10207 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022398738
153 rdf:type schema:CreativeWork
154 https://doi.org/10.1016/0092-8674(93)90133-b schema:sameAs https://app.dimensions.ai/details/publication/pub.1038946067
155 rdf:type schema:CreativeWork
156 https://doi.org/10.1016/j.eururo.2018.03.036 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103237587
157 rdf:type schema:CreativeWork
158 https://doi.org/10.1016/j.humpath.2011.10.014 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009539020
159 rdf:type schema:CreativeWork
160 https://doi.org/10.1021/bc400217g schema:sameAs https://app.dimensions.ai/details/publication/pub.1002281065
161 rdf:type schema:CreativeWork
162 https://doi.org/10.1080/10543409808835252 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038293418
163 rdf:type schema:CreativeWork
164 https://doi.org/10.1083/jcb.201006102 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040781778
165 rdf:type schema:CreativeWork
166 https://doi.org/10.1093/intimm/6.3.477 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059712108
167 rdf:type schema:CreativeWork
168 https://doi.org/10.1097/00000478-200005000-00014 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023798968
169 rdf:type schema:CreativeWork
170 https://doi.org/10.1097/01.ju.0000158121.49085.ba schema:sameAs https://app.dimensions.ai/details/publication/pub.1049100456
171 rdf:type schema:CreativeWork
172 https://doi.org/10.1158/0008-5472.can-05-2883 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027810770
173 rdf:type schema:CreativeWork
174 https://doi.org/10.1158/1078-0432.ccr-15-1542 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015608968
175 rdf:type schema:CreativeWork
176 https://doi.org/10.1158/1535-7163.mct-16-0393 schema:sameAs https://app.dimensions.ai/details/publication/pub.1063226571
177 rdf:type schema:CreativeWork
178 https://doi.org/10.1177/009286150303700108 schema:sameAs https://app.dimensions.ai/details/publication/pub.1063723113
179 rdf:type schema:CreativeWork
180 https://doi.org/10.4049/jimmunol.174.2.710 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027349643
181 rdf:type schema:CreativeWork
182 https://doi.org/10.6004/jnccn.2017.0100 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085942145
183 rdf:type schema:CreativeWork
184 https://www.grid.ac/institutes/grid.14925.3b schema:alternateName Institut Gustave Roussy
185 schema:name Drug Development Department (DITEP), Inserm Unit U981, Université Paris Saclay, Université Paris-Sud, Gustave Roussy, Villejuif, France
186 rdf:type schema:Organization
187 https://www.grid.ac/institutes/grid.417886.4 schema:alternateName Amgen (United States)
188 schema:name Amgen Inc., 91320, Thousand Oaks, CA, USA
189 Amgen Inc., 94080, South San Francisco, CA, USA
190 rdf:type schema:Organization
191 https://www.grid.ac/institutes/grid.419791.3 schema:alternateName Sylvester Comprehensive Cancer Center
192 schema:name Sylvester Comprehensive Cancer Center, University of Miami, 1475 NW 12th Ave, 33136, Miami, FL, USA
193 rdf:type schema:Organization
194 https://www.grid.ac/institutes/grid.477855.c schema:alternateName HonorHealth
195 schema:name HonorHealth Research Institute, 9055 E Del Camino Dr. #100, 85258, Scottsdale, AZ, USA
196 rdf:type schema:Organization
197 https://www.grid.ac/institutes/grid.5253.1 schema:alternateName University Hospital Heidelberg
198 schema:name Department of Medical Oncology, National Center for Tumor Diseases (NCT), Im Neuenheimer Feld 460, 69120, Heidelberg, Germany
199 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...